Zolidime

To aid in the treatment of rheumatism.

this medicine should only be administered when other NSAIDs have not produced satisfactory results and only against acute outbreaks of the following conditions:

* Ankylosing spondylitis.

* Gout.

* Rheumatoid arthritis.

* Osteoarthritis.

this medicine is contraindicated in patients with hypersensitivity to pyrazolones Phenylbutazone (Zolidime) and other derivatives, with obvious gastric ulcer or a history of it, with symptoms or history of inflammatory bowel disease with or without ulceration, blood dyscrasias, or history of them, bleeding diathesis ( thrombocytopenia, coagulation disorders), severe heart failure, liver or kidney disease, severe hypertension, thyroid disease, Sjogren’s syndrome. this medicine is also contraindicated in asthmatic patients in which the making of salicylic acid or other drugs with inhibitory activity of prostaglandin synthetase triggers asthma attacks, urticaria, acute rhinitis or other manifestations of hypersensitivity.

this medicine can increase the activity, the duration of the effect and toxicity of oral anticoagulants (risk of bleeding), the oral agents (risk of serious hypoglycemia) of insulin, phenytoin, sodium valproate, lithium, methotrexate and sulfonamides. this medicine can induce hepatic microsomal metabolism of dicumarol, digitoxin, hexobarbital and cortisone. Inducers of hepatic microsomal enzymes, eg barbiturates, promethazine, chlorpheniramine, rifampicin and corticosteroids (prednisone) may shorten the average life of this medicine.

Conversely, methylphenidate has been reported to prolong the lifetime of this medicine and increases the serum concentration of oxyphenbutazone. Concomitant administration of this medicine with other NSAIDs or corticosteroids increases the risk of causing serious gastrointestinal adverse reactions. Administered together, this medicine and misoprostol can induce adverse symptoms related to central nervous system such as dizziness, headache and transient diplopia.

this medicine may potentiate the effects of alcohol on the central nervous system.

Cholestyramine and antacids reduce this medicine enteral resorption. During concomitant administration of anabolic steroids (methandrostenolone) and this medicine, increases the plasma concentration of oxyphenbutazone.

Gastrointestinal tract:

Common: nausea, gas-tritis.

Occasional: gastrointestinal upset, heartburn, epigastric pain, peptic ulcer, diarrhea.

Rare: vomiting, gastrointestinal bleeding (hematemesis and / or melena), bleeding or perforation of peptic ulcers.

In isolated cases: pancreatitis, esophagitis, esophageal ulcer, benign esophageal narrowing, exacerbation of inflammatory bowel disease, including Crohn’s disease with bleeding, ulceration or perforation, small bowel obstruction, constipation.